New mouse model to improve immune therapy for intrahepatic bile duct (cholangiocarcinoma) cancer
A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy
['FUNDING_R01'] · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · NIH-11392619
This project builds a new mouse model to help make immune-based treatments work better for people with intrahepatic cholangiocarcinoma, a type of bile duct liver cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11392619 on ClinicalTrials.gov |
What this research studies
This project creates a mouse model that mimics intrahepatic cholangiocarcinoma (ICC) so researchers can study the tumor’s immune environment. Scientists will use the model to learn why immune checkpoint drugs have not worked well in ICC and to test combinations that might overcome tumor-driven immunosuppression. The focus is on how CD8 T cells and other immune components interact with ICC tumors and on therapies that could boost anti-tumor immunity. Although the experiments are in mice, the goal is to guide new treatment approaches that could later be tested in people with ICC.
Who could benefit from this research
Good fit: People diagnosed with intrahepatic cholangiocarcinoma (ICC), especially those with advanced disease who need better treatment options, would be the eventual candidates for therapies arising from this work.
Not a fit: Patients without ICC (for example, those with other cancers or non-cancer liver conditions) and people seeking immediate clinical treatment are unlikely to benefit directly from this preclinical mouse-model research.
Why it matters
Potential benefit: If successful, this work could lead to new or better immune-based treatments for patients with intrahepatic cholangiocarcinoma.
How similar studies have performed: Immune checkpoint inhibitors have improved outcomes in hepatocellular carcinoma but have performed poorly in ICC so far, so this approach is relatively new and aims to address that gap.
Where this research is happening
LA JOLLA, UNITED STATES
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KARIN, MICHAEL — SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
- Study coordinator: KARIN, MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Adult-Onset Diabetes Mellitus